The sweet and sour of cancer: Glycans as novel therapeutic targets

Nature Reviews Cancer

Volumn 5, Issue 7, 2005, Pages 526-542

  Fuster, Mark M ^a   Esko, Jeffrey D ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER GROWTH FACTOR; CHONDROITIN SULFATE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GANGLIOSIDE; GCS 100; GD 0039; GLYCAN DERIVATIVE; GLYCOCONJUGATE; GLYCOSAMINOGLYCAN; GLYCOSPHINGOLIPID; GLYCOSYLPHOSPHATIDYLINOSITOL; HEPARAN SULFATE; HEPARIN; HYALURONIC ACID; LECTIN; MUCIN; OLIGOSACCHARIDE; P 188; PECTIN; PHOSPHATIDYLINOSITOL; POLYSACCHARIDE; PROTEIN TYROSINE KINASE; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; SELECTIN; SWAINSONINE; THERATOPE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL ADHESION; CELL CYCLE; CELL INTERACTION; CELL MOTILITY; CELL PROLIFERATION; CELL SURFACE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG SYNTHESIS; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC PROCESSES; NEOVASCULARIZATION, PATHOLOGIC; POLYSACCHARIDES; TUMOR ESCAPE;

EID: 21744431575     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1649     Document Type: Review

References (159)

1. Wells, L., Vosseller, K. & Hart, G. W. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 291, 2376-2378 (2001).
2. Marth, J. Glycosylation changes in ontogeny and cell activation, in Essentials of Glycobiology (eds Varki, A. et al.) 515-536 (Cold Spring Harbor Laboratory Press, New York, 1999).
3. Varki, A. in Essentials of Glycobiology (eds Varki, A. et al.) 537-549 (Cold Spring Harbor Laboratory Press, New York, 1999).
4. Feizl, T. Carbohydrate antigens in human cancer. Cancer Surv. 4, 245-269 (1985).
5. Raedler, A. & Schreiber, S. Analysis of differentiation and transformation of cells by lectins. Crit. Rev. Clin. Lab. Sci. 26, 153-193 (1988).
6. Wels, W. I. & Drickamer, K. Structural basis of lectin-carbohydrate recognition. Annu. Rev. Biochem. 65, 441-473 (1996). Describes the structural basis for sugar recognition and adhesion by lectins expressed in bacteria, animals and plants.
7. Bogenrieder, T. & Herlyn, M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22, 6524-6536 (2003).
8. Hakomori, S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56, 5309-5318 (1996).
9. Iozzo, R. V. & San Antonio, J. D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 108, 349-355 (2001).
10. Liu, D., Shriver, Z., Qi, Y., Venkataraman, G. & Sasisekharan, R. Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin. Thromb. Hemost. 28, 67-78 (2002).
11. Maeder, T. Sweet medicines. Sci. Am. 267, 40-47 (2002).
12. Hollingsworth, M. A. & Swanson, B. J. Mucins in cancer: protection and control of the cell surface. Nature Rev. Cancer 4, 45-60 (2004).
13. Toole, B. P. Hyaluronan: from extracellular glue to pericellular cue. Nature Rev. Cancer A, 528-539 (2004).
14. Felsher, D. W. Reversibility of oncogene-induced cancer. Curr. Opin. Genet. Dev. 14, 37-42 (2004).
15. Marth, J. in Essentials of Glycobiology (eds Varki, A. et al.) 85-100 (Cold Spring Harbor Laboratory Press, New York, 1999).
16. Girnita, L. et al. Inhibition of N-linked glycosylation downregulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications. Anticancer Drug Des. 15, 67-72 (2000).
17. Bharathan, S., Moriarty, J., Moody, C. E. & Sherblom, A. P. Effect of tunicamycin on sialomucin and natural killer susceptibility of rat mammary tumor ascites cells. Cancer Res. 50, 5250-5256 (1990).
18. Komatsu, M., Jepson, S., Arango, M. E., Carothers Carraway, C. A. & Carraway, K. L. Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene 20, 481-470 (2001). Demonstrates how genetic upregulation of MUC4 in tumour A375 melanoma cells inhibits apoptosis of tumour cells and promotes tumour growth in vivo. MUC4 modulates phosphorylation of the receptor tyrosine kinase in the presence and absence of the major EGF receptor ligand, heregulin.
19. Hakomori, S. Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions. J. Biol. Chem. 265, 18713-18716 (1990).
20. Nagy, P. et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J. Cell Sci. 115, 4251-4262 (2002).
21. Esko, J. D. in Essentials of Glycobiology (eds Varki, A. et al.) 145-159 (Cold Spring Harbor Laboratory Press, New York, 1999).
22. Esko, J. D. & Lindahl, U. Molecular diversity of heparan sulfate. J. Clin. Invest. 108, 169-173 (2001).
23. Bernfield, M. et al. Functions of ceil surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729-777 (1999).
24. Kleeff, J. et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J. Clin. Invest. 102, 1662-1673 (1998).
25. Lai, J. et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J. Biol. Chem. 278, 23107-23117 (2003). Demonstration of the importance of HSPGs in tumour proliferation. The cell-surface-associated enzyme SULF1 diminishes HSPG sulphation. Downregulation of SULF1 by tumours increases growth-factor signalling and resistance to apoptosis, representing a novel mechanism by which cancer cells can enhance growth.
26. DeBaun, M. R., Ess, J. & Saunders, S. Simpson Golabi Behmel syndrome: progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition. Mol. Genet. Metab. 72, 279-286 (2001).
27. Filmus, J. Glypicans in growth control and cancer. Glycobiology 11, 19R-23R (2001).
28. Turley, E. A., Noble, P. W. & Bourguignon, L. Y. Signaling properties of hyaluronan receptors. J. Biol. Chem. 277, 4589-4592 (2002).
29. Simpson, M. A., Wilson, C. M. & McCarthy, J. B. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am. J. Pathol. 161, 849-857 (2002).
30. Misra, S., Ghatak, S., Zoltan-Jones, A. & Toole, B. P. Regulation of multidrug resistance in cancer cells by hyaluronan. J. Biol. Chem. 278, 25285-25288 (2003).
31. Chou, T. Y. & Hart, G. W. O-linked N-acetylglucosamine and cancer: messages from the glycosylation of c-Myc. Adv. Exp. Med. Biol. 491, 413-418 (2001). Discusses the importance of modification by O-GlcNAc of key cellular oncogenes or tumour-suppressor proteins. O-GlcNAc transferase glycosylates tumour-suppressor proteins at amino-acid residues that either promote oncogene activity or inhibit tumour-suppressor functions, highlighting the importance of O-GlcNAc in tumorigenesis and tumour proliferation.
32. Noujaim, A. A., Schultes, B. C., Baum, R. P. & Madiyalakan, R. Induction of CA125-specifc B and T cell responses in patients injected with MAb-B43.13 - evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother. Radiopharm. 16, 187-203 (2001).
33. Musselli, C. et al. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int. J. Cancer 97, 660-667 (2002).
34. Ramanathan, R. K. et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54, 254-264 (2005).
35. Bestagno, M., Occhino, M., Comas, M. V., Burrone, O. & Pistoia, V. Recombinant antibodies in the immunotherapy of neuroblastoma: perspectives of new developments. Cancer Lett. 197, 193-198 (2003).
36. Carr, A. et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J. Clin. Oncol. 21, 1015-1021 (2003).
37. Thomas, T. & Thomas, T. J. Polyamine metabolism and cancer. J. Cell Mol. Med. 7, 113-126 (2003).
38. Belting, M. et al. Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc. Natl Acad. Sci. USA 99, 371-376 (2002).
39. Zeng, C., Toole, B. P., Kinney, S. D., Kuo, J. W. & Stamenkovic, I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int. J. Cancer 77, 396-401 (1998). Disruption of the interaction between host tissue stromal hyaluronan and the hyaluronan receptor CD44 on tumour cells can be achieved by treatment with hyaluronan oligomers. This study illustrates how infusion with such oligomers can block growth of experimental melanomas in vivo.
40. Dennis, J. W., Pawling, J., Cheung, P., Partridge, E. & Demetriou, M. UDP-N-acetylglucosamine:α-6-d-mannoside β1, 6N- acetylglucosaminyltransferase V (Mgat5) deficient mice. Biochim. Biophys. Acta. 1573, 414-422 (2002).
41. Yoshimura, M., Ihara, Y., Matsuzawa, Y. & Taniguchi, N. Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis. J. Biol. Chem. 271, 13811-13815 (1996).
42. Hirohashi, S. & Kanai, Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci. 94, 575-581 (2003).
43. Seidenfaden, R., Krauter, A., Schertzinger, F., Gerardy-Schahn, R. & Hildebrandt, H. Polysialic acid directs tumor cell growth by controlling heterophilic neural cell adhesion molecule interactions. Mol. Cell. Biol. 23, 5908-5918 (2003). This study examines the role of polysialic acid on neural cell adhesion molecule (NCAM) in neuroblastoma cells, and demonstrates the ability of polysialic acid to control tumour-cell growth and differentiation by interfering with NCAM signalling at cell-cell contacts.
44. Angata, K. & Fukuda, M. Polysialyltransferases: major players in polysialic acid synthesis on the neural cell adhesion molecule. Biochimie 85, 195-206 (2003).
45. Lin, S., Kemmner, W., Grigull, S. & Schlag, P. M. Cell surface α 2, 6 sialylation affects adhesion of breast carcinoma cells. Exp. Cell Res. 276, 101-110 (2002).
46. Ju, T. & Cummings, R. D. A unique molecular chaperons Cosmc required for activity of the mammalian core 1β 3-galactosyltransferase. Proc. Natl Acad. Sci. USA 99, 16613-16618 (2002).
47. Julien, S. et al. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc.α2, 6-sialyltransferase (ST6GalNac1) cDNA. Glycoconj. J. 18, 883-893 (2001).
48. Quo, H. B., Lee, I., Kamar, M., Akiyama, S. K. & Pierce, M. Aberrant N-glycosylation of β1 integrin causes reduced α5β1 integrin clustering and stimulates cell migration. Cancer Res. 62, 6837-6845 (2002).
49. Wozniak, M. A., Modzelewska, K., Kwong, L. & Keely, P. J. Focal adhesion regulation of cell behavior. Biochim. Biophys. Acta 1692, 103-119 (2004).
50. Tumova, S., Woods, A. & Couchman, J. R. Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int. J. Biochem. Cell Biol. 32, 269-288 (2000).
51. Woods, A., McCarthy, J. B., Furcht, L. T. & Couchman, J. R. A synthetic peptide from the COOH-terminal heparin-binding domain of fibronectin promotes focal adhesion formation. Mol. Biol. Cell 4, 605-613 (1993).
52. Saoncella, S. et al. Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. Proc. Natl Acad. Sci. USA 96, 2805-2810 (1999).
53. Kusano, Y., Yoshitomi, Y., Munesue, S., Okayama, M. & Oguri, K. Cooperation of syndecan-2 and syndecan-4 among cell surface heparan sulfate proteoglycans in the actin cytoskeletal organization of Lewis lung carcinoma cells. J. Biochem. (Tokyo) 135, 129-137 (2004).
54. Culp, L. A. et al. Heparan sulfate proteoglycans of Ras-transformed 3T3 or neuroblastoma cells. Differing functions in adhesion on fibronectin. Ann. NY Acad. Sci. 556, 194-216 (1989).
55. Vlodavsky, I. et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14, 290-302 (1994).
56. Vlodavsky, I. & Friedmann, Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108, 341-347 (2001). Reviews the many roles of heparanase in the tumour environment, and its importance in tumour progression.
57. Kato, M., Saunders, S., Nguyen, H. & Bernfield, M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol. Biol. Cell 6, 559-576 (1995).
58. Beauvais, D. M. & Rapraeger, A. C. Syndecans in tumor cell adhesion and signaling. Reprod. Biol. Endocrinol. 2, 3 (2004).
59. 3 integrin activity in human mammary carcinoma cells. J. Cell Biol. 167, 171-181 (2004).
60. Sanderson, R. D. Heparan sulfate proteoglycans in invasion and metastasis. Semin. Cell Dev. Biol. 12, 89-98 (2001).
61. Iida, J., Meijne, A. M., Knutson, J. R., Furcht, L. T. & McCarthy, J. B. Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin. Cancer Biol. 7, 155-162 (1996).
62. Nutt, C. L., Zerillo, C. A., Kelly, G. M. & Hockfield, S. Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. Cancer Res. 61, 7056-7059 (2001).
63. Faassen, A. E. et al. A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J. Cell Biol. 116, 521-531 (1992).
64. Gunthert, U. et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65, 13-24 (1991).
65. Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B. & Seed, B. CD44 is the principal cell surface receptor for hyaluronate. Cell 61, 1303-1313 (1990).
66. Jalkanen, S. & Jalkanen, M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J. Cell Biol. 116, 817-825 (1992).
67. Wolff, E. A. et al. Generation of artificial proteoglycans containing glycosaminoglycan-modified CD44. Demonstration of the interaction between rantes and chondroitin sulfate. J. Biol. Chem. 274, 2518-2524 (1999).
68. Vlodavsky, I. et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nature Med. 5, 793-802 (1999).
69. Goldshmidt, O. et al. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc. Natl Acad. Sci. USA 99, 10031-10036 (2002).
70. Vlodavsky, I. et al. Molecular properties and involvement of heparanase in cancer progression and normal development. Biochimie 83, 831-839 (2001).
71. Jiang, X. & Couchman, J. R. Perlecan and tumor angiogenesis. J. Histochem. Cytochem. 51, 1393-1410 (2003).
72. Adatia, R. et al. Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA. Ann. Oncol. 8, 1257-1261 (1997).
73. Zcharia, E. et al. Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis. J. Mammary Gland Biol. Neoplasia 6, 311-322 (2001).
74. Granovsky, M. et al. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nature Med. 6, 306-312 (2000). Demonstrates the importance of N-acetylglucosaminyltransferase V (GnTV) in tumour progression by examining mammary tumour growth and metastasis in mice bearing a deletion in the enzyme.
75. Goss, P. E., Baptiste, J., Fernandes, B., Baker, M. & Dennis, J. W. A phase I study of swainsonine in patients with advanced malignancies. Cancer Res. 54, 1450-1457 (1994).
76. Schachter, H. The joys of HexNAc. The synthesis and function of N- and O-glycan branches. Glycoconj. J. 17, 465-483 (2000).
77. Horstkorte, R. et al. Selective inhibition of polysialyltransferase ST8Siall by unnatural sialic acids. Exp. Cell Res. 298, 268-274 (2004).
78. Kakkar, A. K. An expanding role for antithrombotic therapy in cancer patients. Cancer Treat. Rev. 29 (Suppl. 2), 23-26 (2003).
79. Bumol, T. F. & Reisfeld, R. A. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc. Natl Acad. Sci. USA 79, 1245-1249 (1982).
80. Olsen, E. B., Trier, K., Eldov, K. & Ammitzboll, T. Glycosaminoglycans in human breast cancer. Acta Obstet Gynecol. Scand. 67, 539-542 (1988).
81. Lee, C. M. et al. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 62, 4282-4288 (2002).
82. Folkman, J. in The Molecular Basis of Cancer (eds Mendelsohn, J., Howley P. M., Israei M. A. & Liotta L. A.) 206-232 (W. B. Saunders, Philadelphia, 1995).
83. Marcum, J. A. & Rosenberg, R. D. Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem. Biophys. Res. Commun. 126, 365-372 (1985).
84. Zhou, Z. et al. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res. 64, 4699-4702 (2004).
85. Sharma, B. et al. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J. Clin. Invest. 102, 1599-1608 (1998).
86. Folkman, J. & Shing, Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv. Exp. Med. Biol. 313, 355-364 (1992).
87. Zcharia, E. et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J. 18, 252-263 (2004).
88. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407 (1997).
89. Lapierre, F. et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 6, 355-366 (1996).
90. Parish, C. R., Freeman, C., Brown, K. J., Francis, D. J. & Cowden, W. B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 59, 3433-3441 (1999).
91. Presta, M. et al. Heparin derivatives as angiogenesis inhibitors. Curr. Pharm. Des. 9, 553-566 (2003).
92. Liekens, S. et al. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol. Pharmacol. 56, 204-213 (1999).
93. Jemth, P. et al. Biosynthetic oligosaccharide libraries for identification of protein-binding heparan sulfate motifs. Exploring the structural diversity by screening for fibroblast growth factor (FGF)1 and FGF2 binding. J. Biol. Chem. 277, 30567-30573 (2002).
94. Pisano, C. et al. Understated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 15, 1C-6C (2005).
95. Hwang, R. & Varner, J. The role of integrins in tumor angiogenesis. Hematol. Oncol. Clin. North Am. 18, 991-1006, vii (2004).
96. Nguyen, M., Folkman, J. & Bischoff, J. 1-Deoxymannojirimycin inhibits capillary tube formation in vitro. Analysis of N-linked oligosaccharides in bovine capillary endothelial cells. J. Biol. Chem. 267, 26157-26165 (1992).
97. Krause, T. & Turner, G. A. Are selectins involved in metastasis? Clin. Exp. Metastasis 17, 183-192 (1999).
98. Borsig, L. et al. Pictures in molecular medicine: three-dimensional visualization of intravascular tumor cells in mice. Trends Mol. Med. 7, 377 (2001).
99. Cummings, R. D. Selectins. in Essentials of Glycobiology (eds Varki, A. et al.) 391-415 (Cold Spring Harbor Laboratory Press, New York, 1999).
100. Kim, Y. J., Borsig, L., Varki, N. M. & Varki, A. P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl Acad. Sci. USA 95, 9325-9330 (1998). Describes the observation that P-selectin is important for the formation of tumour-platelet emboli during metastasis, and facilitates haematogenous dissemination of mucin-producing carcinoma cells.
101. Borsig, L., Wong, R., Hynes, R. O., Varki, N. M. & Varki, A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl Acad. Sci. USA 99, 2193-2198 (2002).
102. Varki, A. Selectin ligands: will the real ones please stand up? J. Clin. Invest. 100, S31-S35 (1997).
103. Nakamori, S. et al. Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis. Dis. Colon Rectum. 40, 420-431 (1997).
104. Baldus, S. E. et al. Histopathologicai subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: Sialosyl-Lewis(a), Sialosyl-Lewis(x) and sialosyl-Tn. Tumour Biol. 19, 445-453 (1998).
105. Nakamori, S. et al. Molecular mechanism involved in increased expression of sialyl Lewis antigens in ductal carcinoma of the pancreas. J. Exp. Clin. Cancer Res. 18, 425-432 (1999).
106. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
107. Almofti, A. et al. The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. Int. J. Oncol. 25, 65-71 (2004).
108. Crocker, P. R. Siglecs: sialic-add-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr. Opin. Struct. Biol. 12, 609-615 (2002).
109. Brinkman-Van der Linden, E. C. & Varki, A. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. J. Biol. Chem. 275, 8625-8632 (2000).
110. Liu, F. T. & Rabinovich, G. A. Galectins as modulators of tumour progression. Nature Rev. Cancer 5, 29-41 (2005).
111. Pearlstein, E., Salk, P. L., Yogeeswaran, G. & Karpatkin, S. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc. Natl Acad. Sci. USA 77, 4336-4339 (1980).
112. Fuster, M. M., Brown, J. R., Wang, L. & Esko, J. D. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res. 63, 2775-2781 (2003).
113. Al-Mehdi, A. B. et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Med 6, 100-102 (2000).
114. Winn, R. K., Liggitt, D., Vedder, N. B., Paulson, J. C. & Harlan, J. M. Anti-P-selectin monoclonal antibody attenuates reperfusion injury to the rabbit ear. J. Clin. Invest. 92, 2042-2047 (1993).
115. Fukuda, M. N. et al. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res. 60, 450-456 (2000).
116. Kaila, N. & Thomas, B. E. t. Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin inhibitors. Med. Res. Rev. 22, 566-601 (2002).
117. Leppanen, A. et al. A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin. J. Biol. Chem. 274, 24838-24848 (1999).
118. Varki, N. M. & Varki, A. Heparin inhibition of selectin-mediated interactions during the haematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thromb. Hemost. 28, 53-66 (2002).
119. Orner, B. P., Derda, R., Lewis, R. L., Thomson, J. A. & Kiessling, L. L. Arrays for the combinatorial exploration of cell adhesion. J. Am. Chem. Soc. 126, 10808-10809 (2004).
120. Brown, J. R., Fuster, M. M., Whisenant, T. & Esko, J. D. Expression patterns of α 2, 3-sialyltransferases and α 1, 3-fucosyltransferases determine the mode of sialyl Lewis X inhibition by disaccharide decoys. J. Biol. Chem. 278, 23352-23359 (2003).
121. x on the surface of lymphoma cells. This is a novel method to reduce the levels of selectin ligands on a range of carcinomas, thereby altering the metastatic potential of tumour cells.
122. Qian, F., Hanahan, D. & Weissman, I. L. L-selectin can facilitate metastasis to lymph nodes in a transgenic mouse model of carcinogenesis. Proc. Natl Acad. Sci. USA. 98, 3976-3981 (2001).
123. Renkonen, J., Paavonen, T. & Renkonen, R. Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int. J. Cancer 74, 296-300 (1997).
124. Glithero, A. et al. Crystal structures of two H-2Db/ glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity 10, 63-74 (1999).
125. Ibrahim, N. K. & Murray, J. L. Clinical Development of the STn-KLH Vaccine (Theratope(R)). Clin. Breast Cancer 3 (Suppl. 4), 139-143 (2003). The authors describe the development of a unique tumour vaccine by conjugating a synthetic STn epitope to a high-molecular-weight carrier, KLH. The STn-KLH vaccine generates a humoral and cellular immune response, and its safety was confirmed in the ongoing Phase III trial described in the article.
126. Holmberg, L. A., Oparin, D. V., Gooley, T. & Sandmaier, B. M. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the sTn-KLH vaccine (Theratope(R)). Clin. Breast Cancer 3 (Suppl. 4), 144-151 (2003).
127. de Kleijn, E. M. & Punt, C. J. Biological therapy of colorectal cancer. Eur. J. Cancer 38, 1016-1022 (2002).
128. Monzavi-Karbassi, B., Cunto-Amesty, G., Luo, P. & Kieber-Emmons, T. Use of surrogate antigens as vaccines against cancer. Hybrid Hybridomics 21, 103-109 (2002).
129. Lemieux, G. A. & Bertozzi, C. R. Modulating cell surface immunoreactivity by metabolic induction of unnatural carbohydrate antigens. Chem. Biol. 8, 265-275 (2001). Sialic acid is often expressed by tumour-associated oligosaccharide antigens; the authors explored whether intercepting the sialic acid biosynthetic pathway with unnatural precursors might modulate the immunogenicity of targeted tumour cells. Antibodies generated against the unnatural sialic acid directed complement-mediated lysis of tumour cells.
130. Wolff, M., Batten, W. Y., Posovszky, C., Bernhard, H. & Berthold, F. Gangliosides inhibit the development from monocytes to dendritic cells. Clin. Exp. Immunol. 130, 441-448 (2002).
131. Caldwell, S. et al. Mechanisms of ganglioside inhibition of APC function. J. Immunol. 171, 1676-1683 (2003).
132. Freeze, H. H., Sampath, D. & Varki, A. α- and β-xylosides alter glycolipid synthesis in human melanoma and Chinese hamster ovary cells. J. Biol. Chem. 268, 1618-1627 (1993).
133. Weiss, M., Hettmer, S., Smith, P. & Ladisch, S. Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res. 63, 3654-3658 (2003).
134. Ragupathi, G. et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res. 9, 5214-5220 (2003).
135. Slovin, S. F. et al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl Acad. Sci. USA 96, 5710-5715 (1999).
136. Pagnan, G. et al. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J. Natl Cancer Inst. 92, 253-261 (2000).
137. Nakagoe, T. et al. Difference in prognostic value between sialyl Lewis(a) and sialyl Lewis(x) antigen levels in the preoperative serum of gastric cancer patients. J. Clin. Gastroenterol. 34, 408-415 (2002).
138. Nakagoe, T. et al. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients. Hepatogastroenterology 50, 696-699 (2003).
139. Satoh, H. et al. Predictive value of preoperative serum sialyl Lewis X-i antigen levels in non-small cell lung cancer. Anticancer Res. 18, 2865-2868 (1998).
140. Seelenmeyer, C., Wegehingel, S., Lechner, J. & Nickel, W. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J. Cell Sci. 116, 1305-1318 (2003).
141. Hayashi, N. et al. Association between expression levels of CA 19-9 and N-acetylglucosamine-β; 1, 3-galactosyltransferase 5 gene in human pancreatic cancer tissue. Pathobiology 71, 26-34 (2004).
142. Schroeder, J. A., Adriance, M. C., Thompson, M. C., Camenisch, T. D. & Gendler, S. J. MUC1 alters β-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 22, 1324-1332 (2003).
143. Luchansky, S. J., Goon, S. & Bertozzi, C. R. Expanding the diversity of unnatural cell-surface sialic acids. Chembiochem. 5, 371-374 (2004).
144. Saxon, E. & Bertozzi, C. R. Cell surface engineering by a modified Staudinger reaction. Science 287, 2007-2010 (2000).
145. Dwek, R. A., Butters, T. D., Platt, F. M. & Zitzmann, N. Targeting glycosylation as a therapeutic approach. Nature Rev. Drug Discov. 1, 65-75 (2002).
146. Brown, J. R., Fuster, M. M. & Esko, J. D. in Carbohydrate Based Drug Discovery, Vol. 2 (ed. Wong, C.-H.) 883-898 (Wiley VCH, Weinheim, 2003).
147. Fritz, T. A., Lugemwa, F. N., Sarkar, A. K. & Esko, J. D. Biosynthesis of heparan sulfate on β-d-xylosides depends on aglycone structure. J. Biol. Chem. 269, 300-307 (1994).
148. Dimitroff, C. J., Sharma, A. & Bernacki, R. J. Cancer metastasis: a search for therapeutic inhibition. Cancer Invest. 16, 279-290 (1998).
149. Prescher, J. A., Dube, D. H. & Bertozzi, C. R. Chemical remodelling of cell surfaces in living animals. Nature 430, 873-877 (2004).
150. Takenaka, Y., Fukumori, T. & Raz, A. Galectin-3 and metastasis. Glycoconj. J. 19, 543-549 (2004).
151. Kojima, N. & Hakomori, S. Cell adhesion, spreading, and motility of GM3-expressing cells based on glycolipid-glycolipid interaction. J. Biol. Chem. 266, 17552-17558 (1991).
152. Pili, R. et al. The α-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res. 55, 2920-2926 (1995).
153. Kleeff, J. et al. Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells. Pancreas 19, 281-288 (1999).
154. Miyamoto, S. et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 64, 5720-5727 (2004).
155. Derksen, P. W. et al. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99, 1405-1410 (2002).
156. 4 integrin. Semin. Cancer Biol. 14, 115-122 (2004).
157. Syrokou, A., Tzanakakis, G. N., Hjerps, A. & Karamanos, N. K. Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. Biochimie 81, 733-744 (1999).
158. George, D. Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv. Exp. Med. Biol. 532, 141-151 (2003).
159. Wang, L., Fuster, M. M., Sriranardo, P. & Esko, J. D. Endothelial deficiency of heparan sulphate impairs L-selectin and chemokine mediated neutrophil trafficking during inflammatory responses. Nature Immunol. (in the press).